

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/196429 A1

(51) International Patent Classification:
C07D 515/08 (2006.01) A61P 11/00 (2006.01)
C07D 519/00 (2006.01)

(21) International Application Number:
PCT/US2023/017627

(22) International Filing Date:
05 April 2023 (05.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/328,097 06 April 2022 (06.04.2022) US
63/393,405 29 July 2022 (29.07.2022) US

(71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: ABELA, Alexander Russell; 50 Northern Avenue, Boston, Massachusetts 02210 (US). CLEMENS, Jeremy J.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). CLEVELAND, Thomas; 50 Northern Avenue, Boston, Massachusetts 02210 (US). COOK, Christopher; 50 Northern Avenue, Boston, Massachusetts 02210 (US). COON, Timothy Richard; 50 Northern Avenue, Boston, Massachusetts 02210 (US). HADIDA RUAH, Sara Sabina; 50 Northern Avenue, Boston, Massachusetts 02210 (US). KHATUYA, Haripada; 50 Northern Avenue, Boston, Massachusetts 02210 (US). MCCARTNEY, Jason; 50 Northern Avenue, Boston, Massachusetts 02210 (US). MILLER, Mark Thomas; 50 Northern Avenue, Boston, Massachusetts 02210 (US). PIERRE, Fabrice Jean Denis; 50 Northern Avenue, Boston, Massachusetts 02210 (US). UY, Johnny; 50 Northern Avenue, Boston, Massachusetts 02210 (US). ZHOU, Jinglan; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: MCDONELL, Leslie A.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

(57) Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.

WO 2023/196429 A1